Overview

A Study to Evaluate the Bioequivalence of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection in Healthy Study Participants

Status:
Terminated
Trial end date:
2021-04-26
Target enrollment:
Participant gender:
Summary
The purpose of the study is to compare the pharmacokinetics (PK) of bimekizumab when administered subcutaneously (sc) as 1x2 mL versus 2x1 mL, using a bimekizumab-safety syringe presentation or bimekizumab-auto-injector presentation, in healthy study participants.
Phase:
Phase 1
Details
Lead Sponsor:
UCB Biopharma SRL